C
고바이오랩
348150KOSDAQ자연과학 및 공학 연구개발업46.0 / 100
Reference Date: 2026-07-24
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 1.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
KobioLab is a global biotech company leading the development of microbiome-based therapeutics, with a diverse pipeline targeting immune, metabolic, and neurological disorders. Utilizing its proprietary Smartiome platform, the company is conducting global clinical trials and has expanded into the functional food market through its subsidiary, Wibiome.
Number of Employees
57people
Average Salary
57.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 43.644.0Point
PBR
1.27Industry Average 2.525.5Point
Lower than industry avg (good)
ROE
-13.31Industry Average -32.093.5Point
Well below industry avg
Debt Ratio
58.16Industry Average 7.310.0Point
8.0x industry avg (risky)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲53.8% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲11.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.5% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (7%, downtrend)
Current 3,225Won52-week high 6,93052-week low 2,930
1-month return3.0Point
1m -1.83% (flat)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0